Join Dr Charles Pollack for a discussion of his cutting-edge study: Idarucizumab for Dabigatran Reversal — Full Cohort Analysis.
Latest update Time required CPD credits Expiration date
15/09/2017 30 minutes Awaiting CPD accreditation 28/06/2018
  • Target audience

    This educational activity is designed for cardiologists, surgeons, primary care physicians, GPs, nurses and any other healthcare professional with an interest or role in atrial fibrillation management.
  • Learning objectives

    After completing this activity, participants should:

    • Describe how idarucizumab reverses the anticoagulation effects of dabigatran
  • Faculty disclosures

    Dr Charles Pollack

    Thomas Jefferson University Hospital
    Philadelphia, USA

    • Research support from: Boehringer Ingelheim, Janssen Pharma, Portola, Daiichi Sankyo, CSL Behring
    • Consultant for (non promotional): Boehringer Ingelheim, Janssen Pharma, BMS/Pfizer, Portola, Daiichi Sankyo, CSL Behring

    Professor John Camm

    St George's University of London
    London, UK

    • Advisor for: Boehringer Ingelheim, Daiichi Sankyo
    • Consultant (retained) for: Boehringer Ingelheim
    • Received honoraria from: Bayer, Daiichi Sankyo, BMS-Pfizer
  • Staff and reviewer disclosures

    ACHL staff, PCM Scientific staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
  • Financial support

    This independent educational activity is supported by funding from Boehringer Ingelheim. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme.

    The activity is run at arm’s length from the financial supporter and all content is created by the faculty. No funder has had input into the content of the activity.